Chronic rhinosinusitis (CRS) is a chronic inflammatory disease of the paranasal sinuses which represents a significant health burden due to its widespread prevalence and impact on patients' quality of life. As the molecular pathways driving and sustaining inflammation in CRS become better elucidated, the diversity of treatment options is likely to widen significantly. Nanotechnology offers several tools to enhance the effectiveness of topical therapies, which has been limited by factors such as poor drug retention, mucosal permeation and adhesion, removal by epithelial efflux pumps and the inability to effectively penetrate biofilms. In this review, we highlight the successful application of nanomedicine in the field of CRS therapeutics, discuss current limitations and propose opportunities for future work.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2217/nnm-2023-0072 | DOI Listing |
Am J Otolaryngol
December 2024
University of Illinois Chicago College of Medicine, Department of Otolaryngology-Head and Neck Surgery, 1853 W Polk St, Chicago, IL 60612, USA.
Background: Environmental exposures may be associated with increased severity of chronic rhinosinusitis (CRS). However, research examining associations of traffic related air pollution with CRS is limited. The purpose of this study was to determine the association between residential traffic proximity and CRS with nasal polyposis (CRSwNP) severity in an existing database of adults in the United States.
View Article and Find Full Text PDFVestn Otorinolaringol
December 2024
St. Petersburg Research Institute of Ear, Throat, Nose and Speech, St. Petersburg, Russia.
Currently, targeted biological therapy is an innovative and highly effective approach in the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) associated with T2 inflammation that is uncontrolled by standard treatment methods. The article presents the first experience of long-term observation of a patient who, one year after the start of targeted biological therapy with dupilumab, independently stopped the treatment due to complete relief of symptoms of CRSwNP, despite recommendations to continue therapy to maintain control. At the same time, one year after the refusal of biological therapy, the patient showed persistent clinical remission in relation to the symptoms of CRSwNP, confirmed by the results of videoendoscopic examination of the nasal cavity and computed tomography of the sinuses.
View Article and Find Full Text PDFVestn Otorinolaringol
December 2024
Bashkir State Medical University, Ufa, Russia.
Objective: To evaluate the characteristics of antifungal immunity in patients with bilateral chronic rhinosinusitis with nasal polyps.
Material And Methods: The study included 74 patients with bilateral chronic rhinosinusitis with nasal polyps and a control group consisting of 30 almost healthy individuals. All patients underwent surgery and were divided into two groups: Group I - with liquid secretion (=39), Group II - with thick secretion in the paranasal sinuses (=35).
Rhinology
December 2024
Department of Otorhinolaryngology - Head and Neck Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Background: Corticosteroids are used in managing Chronic Rhinosinusitis (CRS) through several formulations, including oral steroids and nasal sprays. More recently, incorporating concentrated budesonide respules into high-volume saline irrigations has been proposed to enhance the penetration of topical steroids into the paranasal sinuses. We aim to evaluate the safety and efficacy of budesonide nasal irrigation (BNI) in managing CRS.
View Article and Find Full Text PDFAdv Respir Med
December 2024
Respiratory Center, Military Hospital 103, Vietnam Military Medical University, Hanoi 12100, Vietnam.
(1) Background: Asthma exacerbations represent significant clinical events, however, the underlying inflammatory mechanisms and cytokine profiles in patients with frequent exacerbations remain incompletely understood; (2) Methods: In this prospective, cross-sectional study of 120 stable asthma patients, we compared the serum concentrations of eight key cytokines (IL-4, IL-12, IL-13, IL-17, IFN-α, IFN-γ, TNF-α, and IL-1β) between two groups: 60 patients with frequent exacerbations (≥ 2 events per year) and 60 matched controls with few exacerbations (1 event per year); (3) Results: Patients with frequent exacerbations showed significantly higher serum concentrations of IL-4 and IL-13 ( < 0.05), along with an increased prevalence of allergic history and comorbidities (chronic rhinosinusitis, GERD, OSA; all < 0.05).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!